SG11201605595YA - Fusion of heterooligomeric mycobacterial antigens - Google Patents

Fusion of heterooligomeric mycobacterial antigens

Info

Publication number
SG11201605595YA
SG11201605595YA SG11201605595YA SG11201605595YA SG11201605595YA SG 11201605595Y A SG11201605595Y A SG 11201605595YA SG 11201605595Y A SG11201605595Y A SG 11201605595YA SG 11201605595Y A SG11201605595Y A SG 11201605595YA SG 11201605595Y A SG11201605595Y A SG 11201605595YA
Authority
SG
Singapore
Prior art keywords
fusion
mycobacterial antigens
heterooligomeric
heterooligomeric mycobacterial
antigens
Prior art date
Application number
SG11201605595YA
Inventor
Jean-Baptiste Marchand
Nathalie Silvestre
François Penin
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of SG11201605595YA publication Critical patent/SG11201605595YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201605595YA 2014-01-09 2015-01-09 Fusion of heterooligomeric mycobacterial antigens SG11201605595YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305030 2014-01-09
PCT/EP2015/050344 WO2015104380A1 (en) 2014-01-09 2015-01-09 Fusion of heterooligomeric mycobacterial antigens

Publications (1)

Publication Number Publication Date
SG11201605595YA true SG11201605595YA (en) 2016-08-30

Family

ID=49989636

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605595YA SG11201605595YA (en) 2014-01-09 2015-01-09 Fusion of heterooligomeric mycobacterial antigens

Country Status (12)

Country Link
US (1) US10765731B2 (en)
EP (1) EP3092000A1 (en)
JP (1) JP6605480B2 (en)
KR (1) KR20160130216A (en)
CN (1) CN106103471B (en)
BR (1) BR112016015936A2 (en)
CA (1) CA2936131A1 (en)
IL (1) IL246659A0 (en)
MX (1) MX2016009072A (en)
RU (1) RU2695462C2 (en)
SG (1) SG11201605595YA (en)
WO (1) WO2015104380A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN105601747B (en) * 2015-10-21 2019-05-28 中山大学 A kind of tubercle bacillus fusion protein and its application in induction peripheral blood mononuclear cells generation cell factor
CN105218680B (en) * 2015-10-21 2019-06-25 中山大学 It is a kind of for induce peripheral blood mononuclear cells generate cell factor Mycobacterium tuberculosis fusion protein
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
US20200148729A1 (en) * 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
WO2017223146A1 (en) * 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
EP3697806A4 (en) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberculosis antigen cassettes
KR102004902B1 (en) * 2017-12-26 2019-07-29 연세대학교 산학협력단 Composition for tuberculosis comprising fusion protein
CN110684116B (en) * 2019-08-23 2022-04-26 成都可恩生物科技有限公司 Mycobacterium tuberculosis EEC fusion protein, preparation method and application thereof
CN110590957B (en) * 2019-09-11 2021-06-01 中国人民解放军总医院第八医学中心 Fusion protein and application thereof in immune protection against mycobacterium tuberculosis
RU2724896C1 (en) * 2019-11-14 2020-06-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Polyantigenic vaccine for preventing and adjunctive treatment of tuberculosis
CN111269297B (en) * 2020-01-23 2021-11-30 郑州伊美诺生物技术有限公司 Preparation method of mycobacterium tuberculosis stimulating antigen
WO2024027910A1 (en) * 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024028445A1 (en) * 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN116162141B (en) * 2022-11-30 2024-04-12 中国疾病预防控制中心传染病预防控制所 Mycobacterium tuberculosis antigen EPCRA013 and application thereof
CN116063418B (en) * 2022-12-08 2024-04-12 中国疾病预防控制中心传染病预防控制所 Mycobacterium tuberculosis antigen composition EPPA 015, and preparation method and application thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP3602530B2 (en) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション Genetically engineered vaccine strain
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
EP0833934B2 (en) 1995-06-15 2012-08-15 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
FR2751343B1 (en) 1996-07-16 1998-12-18 Transgene Sa PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
PL341697A1 (en) * 1997-12-23 2001-04-23 Genesis Res & Dev Corp Ltd Compositions derived from mycobacterium vaccae and methods of using them
US6328978B1 (en) * 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
EP1155120B1 (en) 1999-02-22 2006-07-05 Transgene S.A. Method for obtaining a purified viral preparation
ATE445018T1 (en) 1999-05-17 2009-10-15 Crucell Holland Bv ADENOVIRUS-DERIVED GENE TRANSFER VEHICLES CONTAINING AT LEAST ONE ELEMENT OF ADENOVIRUS TYPE 35
AU2002231639B2 (en) 2000-11-23 2007-01-04 Bavarian Nordic A/S Modified vaccinia ankara virus variant
JP2005504523A (en) 2001-06-22 2005-02-17 ヘルス プロテクション エージェンシー Mycobacterial antigen expressed under hypoxic pressure
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
UA82466C2 (en) 2001-07-18 2008-04-25 Бавариан Нордика А/С Method for intensification of chordopoxvirus amplification
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
MXPA04005577A (en) 2001-12-10 2005-04-19 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions.
FR2836924B1 (en) 2002-03-08 2005-01-14 Vivalis AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004083418A1 (en) 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
AU2003298554A1 (en) 2003-03-28 2004-11-23 Merck & Co., Inc. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
PL2163260T3 (en) 2004-01-23 2017-12-29 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
CA2837748C (en) * 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
US20060024332A1 (en) * 2004-08-02 2006-02-02 Waters Wade R Recombinant ESAT-6:CFP-10 fusion protein useful for specific diagnosis of tuberculosis
EP1786460A4 (en) * 2004-08-26 2008-04-02 Sequella Inc Assay for detecting tuberculosis in nonhuman primates
JP2008526823A (en) * 2005-01-05 2008-07-24 アイシス イノヴェーション リミテッド Compositions that immunize against mycobacteria
AU2006229549B2 (en) 2005-03-31 2011-04-07 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of Mycobacterium infections and tuberculosis disease
KR101035053B1 (en) * 2005-06-23 2011-05-19 스태튼스 세룸 인스티튜트 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
NZ597557A (en) 2006-03-02 2013-10-25 Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
JP2009541236A (en) 2006-06-20 2009-11-26 トランジェーヌ、ソシエテ、アノニム Recombinant virus vaccine
PL2136836T3 (en) 2007-04-04 2017-07-31 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
PL2167124T3 (en) * 2007-06-29 2012-12-31 Statens Seruminstitut The use of monomycolyl glycerol (mmg) as an adjuvant
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
JP5421250B2 (en) 2007-07-03 2014-02-19 トランスジーン ソシエテ アノニム Avian immortal cell line
CN101376891B (en) * 2007-08-27 2012-05-23 上海生物制品研究所有限责任公司 Preparation of novel tuberculosis vaccine and use thereof
US7935354B2 (en) 2007-11-13 2011-05-03 Aeras Global Tb Vaccine Foundation Generation of new BCG vaccine strains protecting against the establishment of latent Mycobacterium tuberculosis infection and reactivation from the latent or persistent state
EP2385371B1 (en) * 2008-09-22 2014-10-22 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
WO2010034974A2 (en) * 2008-09-24 2010-04-01 Adjuvantix Limited Tb vaccine
CN101538578B (en) * 2009-03-02 2011-01-26 华中农业大学 Recombinant bovine tuberculosis specific antigen protein with three fused genes and preparation method thereof
PL2421557T3 (en) * 2009-04-24 2019-07-31 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
CA2760465A1 (en) 2009-05-12 2010-11-18 Transgene Sa Method for orthopoxvirus production and purification
ES2661215T3 (en) 2009-05-20 2018-03-28 Aeras Viral compositions; immunogens; spray dried; stable
GB201007790D0 (en) * 2010-05-10 2010-06-23 Isis Innovation Compositions
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
CN101900727A (en) * 2010-06-01 2010-12-01 华中农业大学 Bovine tuberculosis antibody identifying and detecting test strip prepared by applying Rv3872 novel fusion protein
WO2012031752A2 (en) 2010-09-07 2012-03-15 Institut Pasteur Korea Tuberculosis mutants
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
WO2012129227A1 (en) * 2011-03-22 2012-09-27 Baylor Research Institute Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine
CN102692509B (en) * 2012-05-11 2014-11-26 中国农业科学院北京畜牧兽医研究所 Method for diagnosing bovine tuberculosis mediated by recombinant protein mixture and regent thereof
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) * 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CN102719438B (en) 2012-07-12 2013-10-30 章晓联 Nucleic acid aptamer capable of being specifically bound to tubercle bacillus antigen and application thereof
IN2015DN03962A (en) 2012-10-23 2015-10-02 Statens Seruminstitut
CN103333251B (en) * 2013-04-11 2014-08-20 广西壮族自治区动物疫病预防控制中心 Gamma-interferon sandwich ELISA detection method based on recombinant fusion antigen protein
CN103204945A (en) 2013-05-03 2013-07-17 扬州大学 Eukaryotic expression CFP10-ESAT-6 fusion protein for diagnosis of bovine tuberculosis
CN105431166B (en) 2013-06-25 2020-09-18 国际艾滋病疫苗行动组织公司 Tuberculosis compositions and methods of use thereof
CN103386128B (en) 2013-07-02 2017-02-08 中国食品药品检定研究院 Tuberculosis subunit vaccine containing unite adjuvant

Also Published As

Publication number Publication date
KR20160130216A (en) 2016-11-10
RU2016131853A (en) 2018-02-12
CN106103471B (en) 2020-01-07
BR112016015936A2 (en) 2017-09-19
JP6605480B2 (en) 2019-11-13
CA2936131A1 (en) 2015-07-16
US10765731B2 (en) 2020-09-08
RU2016131853A3 (en) 2018-06-26
JP2017505605A (en) 2017-02-23
US20160331823A1 (en) 2016-11-17
MX2016009072A (en) 2017-05-08
RU2695462C2 (en) 2019-07-23
WO2015104380A1 (en) 2015-07-16
IL246659A0 (en) 2016-08-31
CN106103471A (en) 2016-11-09
EP3092000A1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
IL246659A0 (en) Fusion of heterooligomeric mycobacterial antigens
IL249607B (en) Tnf-alpha antibodies
AP2017009765A0 (en) Anti-tigit antibodies
IL246355B (en) P97-ids fusion proteins
LT3149345T (en) Method of joining two objects
GB201419859D0 (en) No title listed
EP3185820A4 (en) Fusion device
IL246909A0 (en) Il-21 antibodies
ZA201701461B (en) Antibody formulations
IL250374A0 (en) Anti-ceramide antibodies
IL282104A (en) Mutant staphylococcal antigens
SG11201702517YA (en) Navigating application interface
GB201400819D0 (en) Mycobacterial antigen composition
EP3233120A4 (en) Il-21 antibodies
PT3126521T (en) Hnf4g-rspo2 fusion gene
GB201421718D0 (en) Underwater engagement of tubular members
GB2529844B (en) Forming butted tubes
AU2014905159A0 (en) IL-21 antibodies
GB201415526D0 (en) Antibody Formulations
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201415298D0 (en) Antibody Formulations
GB201417614D0 (en) Antibodies
AU2014903442A0 (en) Fusion device
GB201414270D0 (en) Antibodies